BTAI earnings: real EPS beat/miss history, analyst consensus Buy, P/E -0.13. Updated 2026-07-23.
BioXcel Therapeutics (BTAI) Research Hub
BioXcel Therapeutics (BTAI) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-08, shares last closed at 0.043 USD (-41.89%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.13, market cap 0.03B. This hub links to the full technical, earnings and options research available for BTAI.
Last updated 2026-09-08 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 0.043 USD (-41.89%) |
| 52-week range | 0.019 USD – 1.43 USD |
| Trend regime | Range |
| 14-day RSI | 22.6 (Oversold) |
| Trailing P/E | -0.13 |
| Market cap | 0.03B |
| Dividend yield | 0.00% |
Available research for BTAI
Covered Call on BTAI: how it works, illustrative setup around the real 0.043 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on BTAI: how it works, illustrative setup around the real 0.043 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on BTAI: how it works, illustrative setup around the real 0.043 USD price, max profit/loss, breakeven and when to use it. Educational.
BTAI technical analysis: range, last 0.043 USD, RSI 22.6, 52w range 0.019 USD–1.43 USD, real support/resistance. Updated 2026-09-08.
Frequently asked questions
What sector is BTAI in?
BioXcel Therapeutics (BTAI) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is BTAI in an uptrend or downtrend?
As of 2026-09-08, BTAI is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is BTAI's trailing P/E ratio?
BTAI's trailing P/E is -0.13, with a market cap of 0.03B. See the earnings research page for full valuation detail.